About: Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020
Creator	Lindquist, Scott Wiesman, John Klena, John Reed, Carrie Pritchard, Scott Lester, Sandra Roguski, Katherine Montgomery, Joel Turabelidze, George Freeman, Brandi Fry, Alicia Hall, Aron Lim, Travis Havers, Fiona Blackmore, Carina Owen, S Thornburg, Natalie Carroll, Darin Blog, Debra Cannon, Deborah Chiang, Cheng-Feng Drph, Washington Dunn, Angela Gibbons, Aridth Johnson, Jeffrey Krapiunaya, Inna Mills, Lisa Morales-Betoulle, Maria Rasheed, Mohammad Schiffer, Jarad Semenova, Vera State, New Williams, Randall
Source	MedRxiv
abstract	Importance: Reported cases of SARS-CoV-2 infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected. Objective: To estimate prevalence of SARS-CoV-2 antibodies in convenience samples from several geographic sites in the United States. Design: Serologic testing of convenience samples using residual sera obtained for routine clinical testing by two commercial laboratory companies. Setting: Connecticut (CT), south Florida (FL), Missouri (MO), New York City metro region (NYC), Utah (UT), and Washington State's (WA) Puget Sound region. Participants: Persons of all ages with serum collected during intervals from March 23 through May 3, 2020. Exposure: SARS-CoV-2 virus infection. Main outcomes and measures: We estimated the presence of antibodies to SARS-CoV-2 spike protein using an ELISA assay. We standardized estimates to the site populations by age and sex. Estimates were adjusted for test performance characteristics (96.0% sensitivity and 99.3% specificity). We estimated the number of infections in each site by extrapolating seroprevalence to site populations. We compared estimated infections to number of reported COVID-19 cases as of last specimen collection date. Results: We tested sera from 11,933 persons. Adjusted estimates of the proportion of persons seroreactive to the SARS-CoV-2 spike protein ranged from 1.13% (95% confidence interval [CI] 0.70-1.94) in WA to 6.93% (95% CI 5.02-8.92) in NYC (collected March 23-April 1). For sites with later collection dates, estimates ranged from 1.85% (95% CI 1.00-3.23, collected April 6-10) for FL to 4.94% (95% CI 3.61-6.52) for CT (April 26-May 3). The estimated number of infections ranged from 6 to 24 times the number of reported cases in each site. Conclusions and relevance: Our seroprevalence estimates suggest that for five of six U.S. sites, from late March to early May 2020, >10 times more SARS-CoV-2 infections occurred than the number of reported cases. Seroprevalence and under-ascertainment varied by site and specimen collection period. Most specimens from each site had no evidence of antibody to SARS-CoV-2. Tracking population seroprevalence serially, in a variety of specific geographic sites, will inform models of transmission dynamics and guide future community-wide public health measures.
has issue date	2020-06-26(xsd:dateTime)
bibo:doi	10.1101/2020.06.25.20140384
has license	medrxiv
sha1sum (hex)	f718309243343298bb5cac689c63083f47e25f5d
schema:url	https://doi.org/10.1101/2020.06.25.20140384
resource representing a document's title	Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020
resource representing a document's body	covid:f718309243343298bb5cac689c63083f47e25f5d#body_text
is schema:about of	named entity 'intervals' named entity 'Collaborator' named entity 'CASE REPORT' named entity 'ESTIMATE' named entity 'CLINICAL' named entity 'case report' named entity 'Estimates' named entity 'residual' named entity 'Florida' named entity 'Connecticut' named entity 'New York City' named entity 'antibodies' named entity 'preprint' named entity 'antibodies' named entity 'preprint' named entity 'medRxiv' named entity 'IgG antibodies' named entity 'medical care' named entity 'projected set' named entity 'SARS-CoV-2' named entity 'CC0' named entity 'zip code' named entity 'zip code' named entity 'preprint' named entity 'seroprevalence' named entity 'seroprevalence' named entity 'SARS-CoV-2' named entity 'seroprevalence' named entity 'confidence interval' named entity 'health care' named entity 'CC0' named entity 'reported cases' named entity 'CDC' named entity 'preprint' named entity 'polymerase' named entity 'IgM' named entity 'CC0' named entity 'Seroprevalence' named entity 'medRxiv' named entity 'preprint' named entity 'seroprevalence' named entity 'preprint' named entity 'Seroprevalence' named entity 'NYC.' named entity 'seroprevalence' named entity 'SARS-CoV-2' named entity 'RT-PCR' named entity 'symptom' named entity 'reported cases' named entity 'community transmission' named entity 'SARS-CoV-2 virus' named entity 'viral testing' named entity 'seroprevalence'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software